Solid Biosciences’ SGT-003 receives rare pediatric disease designation

The trial will involve two cohorts, with cohort 1 including DMD patients aged four to less than six and cohort 2 with patients aged six to less than eight. Credit: Kelly Sikkema/Unsplash.